<SEC-DOCUMENT>0001062993-16-010518.txt : 20160712
<SEC-HEADER>0001062993-16-010518.hdr.sgml : 20160712
<ACCEPTANCE-DATETIME>20160712155108
ACCESSION NUMBER:		0001062993-16-010518
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20160712
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160712
DATE AS OF CHANGE:		20160712

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		161763988

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 950, 1130 WEST PENDER STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E 4A4
		BUSINESS PHONE:		604-602-1675

	MAIL ADDRESS:	
		STREET 1:		SUITE 950, 1130 WEST PENDER STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E 4A4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Form 8-K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION</FONT></B><BR>Washington, D.C. 20549
</P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center><B>CURRENT REPORT </B></P>
<P align=center>Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934 </P>
<P align=center>Date of Report (Date of earliest event reported) <B><U>July 12,
2016</U></B></P>
<P align=center><B><U><FONT size=5>LEXARIA BIOSCIENCE CORP.</FONT></U></B><B>
</B><BR>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD align=center width="33%"><B><U>000-52138 </U></B></TD>
  <TD align=center width="33%"><B><U>20-2000871 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of </TD>
    <TD align=center width="33%">(Commission File Number) </TD>
  <TD align=center width="33%">(IRS Employer </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>incorporation) </TD>
    <TD align=center width="33%">&nbsp; </TD>
  <TD align=center width="33%">Identification No.) </TD>
  </TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>#950 &#150; 1130 West Pender Street, Vancouver, BC
      Canada</U></B></TD>
  <TD align=center width="31%" ><B><U>V6E 4A4 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(Address of principal executive offices) </TD>
  <TD align=center width="31%" >(Zip Code) </TD>
  </TR>
  <TR>
    <TD align="center">&nbsp; </TD>
  <TD width="31%" align="center" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD colspan="2" align=center>Registrant&#146;s telephone number, including area code &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>(604) 602-1675 </u></b></TD>
  </TR></TABLE>
<P align=justify><B><U>LEXARIA CORP.</U></B><B> </B><BR>(Former name or former
address, if changed since last report.) <BR></P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</P>
<P align=justify>[ &nbsp; ]&nbsp; Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)<BR>[&nbsp;&nbsp; ]&nbsp; Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a
-12)<BR>[&nbsp;&nbsp; ]&nbsp; Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))<BR>[&nbsp;&nbsp; ]&nbsp;
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e -4(c))<BR></P>
<P align=justify><B>Item 7.01&nbsp;&nbsp; Regulation FD Disclosure </B></P>
<P align=justify>A copy of the news release announcing that we have received our
first Notice of Allowance for one of our US patent applications from the US
Patent and Trademark Office is filed as exhibit 99.1 to this current report and
is hereby incorporated by reference. </P>
<P align=justify><B>Item 9.01&nbsp;&nbsp; &nbsp;Financial Statements and
Exhibits </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="exhibit99-1.htm">99.1 </a></TD>
    <TD align=left width="90%" bgColor=#eeeeee ><a href="exhibit99-1.htm">Press Release
      dated July 12, 2016 </a></TD>
  </TR></TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=center>- 2 - </P>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<P align=justify><B>LEXARIA BIOSCIENCE CORP.</B> </P>
<P align=justify>&nbsp;</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/ Chris
      Bunka</I> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Chris Bunka</B> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>CEO, Principal Executive Officer </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Date: July 12, 2016 </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR></TABLE><BR>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=right>Exhibit 99.1 </P>
<P align=center><B>Lexaria Receives Notice of Allowance of First Patent by US
Patent Office </B></P>
<P align=justify>Kelowna, BC / July 12, 2016 / Lexaria Bioscience Corp.
(OTCQB:LXRP) (CSE:LXX) (the &#147;Company&#148;) is very pleased to announce a watershed
event in its advancement as a bioscience company: it has just received its first
Notice of Allowance for one of its US patent applications from the US Patent and
Trademark Office (USPTO). </P>
<P align=justify>Lexaria is very pleased at the unexpectedly rapid allowance of
these first claims protecting its intellectual property portfolio by the USPTO,
and has every reason to believe this is only the first of what will be several
successful patent applications. The Notice of Allowance concludes the
substantive examination of US Patent Application Serial No. 14/735,844 by the
USPTO and will result in the issuance of a US patent after remaining
administrative processes are completed in the next several weeks. The US patent
scheduled to issue from this application will expire no earlier than June 10,
2035. </P>
<P align=justify>This patent application allowance adds value to the Company in
three crucial ways: </P>
<P align=justify>First, the issued patent will provide us with the exclusive
right to prevent others from making, using, selling, or importing the claimed
invention in the US, and the right to collect damages for any such unlawful
activity. This greatly strengthens our competitive position and elevates the
relative value of our intellectual property (IP). </P>
<P align=justify>Second, it strengthens the Company&#146;s financial leverage for
existing and future technology licensing agreement negotiations with our
USPTO-recognized IP. Lexaria previously began monetizing its IP in May 2016 with
our first licensing agreement, and is now in a stronger position than ever to
both continue and even accelerate this process. </P>
<P align=justify>Third, it strengthens our optimism that the Company will
achieve similar success with additional IP claims it has filed with the USPTO
and under the international Patent Cooperation Treaty (PCT). As Lexaria
continues to expand its allowable and issued patent portfolio, its ability to
enter additional technology licensing agreements should greatly expand. </P>
<P align=justify>The title of the patent application allowed by the USPTO is
&#147;Food and Beverage Compositions Infused with Lipophilic Active Agents and Method
of Use Thereof&#148;. The allowed application includes a series of Lexaria&#146;s method
claims for combining a lipophilic active agent together with a bioavailability
and taste enhancing oil by way of dehydration or lyophilization, and doing so in
contact with a food product substrate material. Lexaria still has a number of
additional patent applications undergoing review by the USPTO and patent
application continuations planned in order to further broaden its expected set
of compositional and method patent claims regarding the technology. As a result,
it is not possible to know how many additional allowed patents may be achievable
although there could be many. </P>
<P align=justify>&#147;Lexaria believes that anytime and every time it is successful
in progressing a patent application into a granted patent, it not only
reinforces the validity of its underlying encapsulation technology, but it also
opens new areas of potential revenue generation and economic activity,&#148; said
John Docherty, President of the Company. &#147;Lexaria&#146;s allowed and pending patent
portfolio is both broad and deep and its executives continue to investigate
additional new areas of IP that could be symbiotic with that which is already
known.&#148;</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=justify>Lexaria&#146;s business plan is focused in part on the leveraging of its IP
prowess in disparate areas of the economy, such as the rapidly evolving cannabinoid sector;
the vitamin sector; the NSAID sector; and even the nicotine sector. Lexaria&#146;s
unique technology allows for more efficient and effective absorption of
molecules such as these, while simultaneously masking, and at times even
eliminating, inherent strong flavours and/or odors typical of those molecules.
Lexaria&#146;s technology is extremely cost effective to implement and applicable to
the widest imaginable spectrum of foods including but not limited to chocolates,
candies, coffee, tea, a wide variety of other beverages, protein bars, cookies,
pastas, entrees, breads, and much more. </P>
<P align=justify>The Company is grateful for the dedication and vision of its
technology founders, of its talented IP team, and of its management team who
have together guided this successful process.</P>
<P align=justify>About Lexaria <BR>Lexaria Bioscience Corp. is a food sciences
company focused on the delivery of active compounds that can behave as
superfoods through its proprietary infusion technologies. Lexaria&#146;s technology
enables higher bioavailability rates for CBD; THC; NSAIDs; Nicotine and other
molecules than is possible without lipophilic enhancement technology. This can
allow for lower overall dosing requirements and/or higher effectiveness in
active molecule delivery. Lexaria hopes to reduce other common but less healthy
ingestion methods such as smoking as it embraces the benefits of public health.
www.lexariaenergy.com </P>
<P align=justify>FOR FURTHER INFORMATION PLEASE CONTACT:</P>
<P align=justify>Lexaria Bioscience Corp.<BR>Chris Bunka<BR>Chairman &amp;
CEO<BR>(250) 765-6424 <BR></P>
<P align=justify>FORWARD-LOOKING STATEMENTS </P>
<P align=justify>This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to: any
revenue or license fee payments that may be realized from the license agreement,
the introduction of any product lines that are derived from the license
agreement, that any similar license arrangements may be entered into with other
companies or partners, that the Company&#146;s technology enables higher rates of
absorption of certain molecules such as vitamins and cannabinoids while
simultaneously masking and at times even eliminating inherent strong flavors
and/or odors typical of those molecules, or that the technology will function in
a similar manner if tested with THC, nicotine, or any of the other molecules
named in our patent applications. Such forward-looking statements are estimates
reflecting the Company's best judgment based upon current information and
involve a number of risks and uncertainties, and there can be no assurance that
other factors will not affect the accuracy of such forward-looking statements.
Access to capital, or lack thereof, is a major risk and there is no assurance
that the Company will be able to raise required working capital. Factors which
could cause actual results to differ materially from those estimated by the
Company include, but are not limited to, government regulation, managing and
maintaining growth, the effect of adverse publicity, litigation, competition,
the patent application and approval process and other factors which may be
identified from time to time in the Company's public announcements and filings.
There is no assurance that the license agreement, hemp oil sector, or
alternative health businesses will provide any benefit to Lexaria, or that the
Company will experience any growth through participation in these sectors or as
a result of the license agreement. There is no assurance that existing capital
is sufficient for the Company's needs or that it will be able to raise
additional capital. There is no assurance that any planned corporate activity,
business venture, or initiative will be pursued, or if pursued, will be
successful. There is no assurance that any patent application in the USA or any
other nation or under any treaty will result in the award of an actual patent;
nor that an award of any actual patent will protect against challenges from
unknown third parties. There is no assurance that any definitive agreement will
be reached to license the Company&#146;s technology to any third party in return for
compensation. There is no assurance that the Company&#146;s competitive position,
financial leverage, or likelihood of receiving additional patent allowances will
be improved as a result of the current patent allowance by the USPTO. There is
no assurance that any of Lexaria&rsquo;s postulated uses, benefits, or advantages for the patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA).
ViPova<SUP>TM</SUP> products are not intended to diagnose, treat, cure or prevent any disease.</P>
<P align="justify">
<I>The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. </I></P>

<HR noshade align="center" width="100%" size=5 color="black">


</BODY>

</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
